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NCI 60-cell panel assayAbstract A series of 3-substituted-4-chloro-thioxanthones and their corresponding
S,S-dioxidethioxanthone derivatives were designed and synthesized. The effects of our synthesized
compounds on cell viability toward the MCF-7 and MDA-MB-468 breast cancer cell lines were
evaluated. The most active compound was 4f, which was active against the MCF-7 and
MDA-MB-468 cell lines with respective IC50 values of 7.2 and 3.9 lM. Interestingly, compound
4f did not impair cell viability of the cardiac myoblast H9C2 cell line (IC50 > 25 lM), indicating
that this compound might not exhibit cytotoxic effects on the normal cardiac cells. Further, com-
pounds 4b, 4f, 4j, 4s, 5b, 5f, 5j, and 5s were characterized by the NCI screening system. Results
revealed that compounds 4f and 4s had effective anticancer activities against various cancer cell
lines. Finally, our results indicated that the 3-substituted-4-chloro-thioxanthone derivatives have
the potential to be further developed as promising small molecules for anticancer applications.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Thioxanthones belong to an important class of synthetic com-
pounds, which have been studied and described since 1891
(Graebe and Schultess, 1891; Paiva et al., 2013). They are
structurally similar to xanthone, acridone, and anthraquinone
tricyclic scaffolds (Pouli and Marakos, 2009; Belmont and
Dorange, 2008; Huang et al., 2007), and were found to exhibitt cancer
2 C.-L. Chen et al.interesting chemical properties including photoinitiated
polymerization (Davidson et al., 1983; Fouassier and Rabek,
1993; Yilmaz et al., 2010; Mishra and Yusuf, 2008). Thioxan-
thones also reveal unique pharmacologic characteristics
depending on the structure and scaffold substituents (Paiva
et al., 2013; Pouli and Marakos, 2009). Over the years, thiox-
anthone derivatives have been extensively synthesized and
studied owing to their diverse biological activities such as
antischistosomal effects (Archer et al., 1988), antibiotic activity
(Bessa et al., 2015; Verbanac et al., 2012), monoamine oxidase
inhibitory activity (Harfenist et al., 1996), activation of
P-glycoprotein (Silva et al., 2015), and especially their antitu-
mor activities (Woo et al., 2008; Kostakis et al., 2001;
Palmeira et al., 2012). Interestingly, hycanthone as one of
the thioxanthone derivatives (Fig. 1), was found to exhibit
antischistosomal, antitumor, and anti-metastatic activities
against breast cancer, so it was selected to proceed to clinical
trials as an anticancer drug candidate in the 1980s, but was
withdrawn due to its toxicity and mutagenicity (Paiva et al.,
2013; Cioli et al., 1995). After chemical modification,
SR271425, a third-generation thioxanthone compound derived
from hycanthone, was developed and entered clinical trials
based on robust in vivo antitumor activity, but it did not pro-
ceed due to its cardiotoxicity (Goncalves et al., 2008; Campone
et al., 2007; Lockhart et al., 2009). Because of the potential
demonstrated by this scaffold, thioxanthone is still a promising
lead structure as an anticancer agent that warrants further lead
optimization. Therefore, the development of new thioxanthone
analogs with potential anticancer properties and determination
of their structure–activity relationships remain attractive goals
in cancer research.
In this report, we synthesized 38 new thioxanthone analogs
(4a–4s, 5a–5s) bearing various substituents. The thioxanthone
core (4a) was prepared by the Ullmann condensation reaction
and Friedel–Crafts intramolecular ring closure reaction based
on the literature (Jı´lek et al., 1981; Lory et al., 2006). Accord-
ing to the literature, we noted that introduction of a suitable
functional group at the 3-position of the thioxanthone scaffold
could enhance the pharmacophore motifs required for biolog-
ical activities, especially anticancer activity (Woo et al., 2008;
Chae et al., 2015). In order to understand the structure–
activity relationships of the substituents at the 3-position
of thioxanthones, we prepared a series of thioxanthoneFigure 1 Structures related to thioxan
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at the 3-position of the core structure. Based on previous stud-
ies, S,S-dioxidethioxanthone analogs derived from thioxan-
thone were shown to possess potential biological activities
(Harfenist et al., 1997; Christodoulou et al., 2011). In order
to verify the significance of the biologic activities of the
S,S-dioxide group on the thioxanthone scaffold, we prepared
corresponding S,S-dioxidethioxanthone analogs (5a–5s) of
the thioxanthones (4a–4s).
Based on published reports revealing that thioxanthone
derivatives exhibit potent anticancer activities toward several
cancer types such as breast cancer (Verbanac et al., 2012;
Woo et al., 2008; Palmeira et al., 2012; Varvaresou et al.,
1996), we evaluated the effects of our synthetic thioxanthone
derivatives (4a–4s and 5a–5s) on cell viability of the MCF-7
andMDA-MB-468 breast cancer cell lines using anMTT assay.
Further, we tested the toxicities of our thioxanthone derivatives
against theH9C2 cardiomyoblastic cell line as a normal cell con-
trol to detect any cytotoxicity of our compounds toward normal
cells.Moreover, compounds 4b (NSC753740), 5b (NSC763938),
4f (NSC753748), 5f (NSC763940), 4j (NSC753741), 5j
(NSC763942), 4s (NSC753744) and 5s (NSC763947) were
selected by the NCI to test under a one-dose screening program.
Results showed that compound 4f was the most-active deriva-
tive against the MCF-7 and MDA-MB-468 breast cancer cell
lines without remarkable cytotoxicity toward the normal
H9C2 cells.
2. Chemistry
2.1. Materials and instruments
The synthesis procedures and physical data of compounds 4a–
4s and 5a–5s are described in this investigation. We investi-
gated the role of the systematic heterocyclic pharmacophore
and introduced a series of substituted phenylthio groups linked
to the thioxanthone core structure (Scheme 1). All chemicals
and solvents used were commercially available, and were pur-
chased from Aldrich or Merck without further purification. All
reactions were monitored by analytical TLC (silica gel 60 F254)
using various solvent systems. Melting points were determined
in open capillary tubes with a Bu¨chi 545 melting point
determination apparatus. Both 1H-nuclear magnetic resonancethone and thioxanthone derivatives.
ew 3-substituted-4-chloro-thioxanthone derivatives as potent anti-breast cancer
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Scheme 1 aOverall synthetic routes of the 3-substituted-4-chloro-thioxanthone analogs. aReagents and conditions: (i) 1 M KOH(aq), Cu,
DMF, 120 C, 8 h. (ii) 75% H2SO4(aq), 110 C, 6 h, miniclave. (iii) RSH, NaOCH3, MeOH, THF, reflux, 2 h. (iv) H2O2, HOAc, reflux, 2 h.
(v) RSH, NaOCH3, MeOH, THF, reflux, 2 h.
Synthesis and evaluation of 3-substituted-4-chloro-thioxanthone derivatives 3(NMR) and 13C NMR spectra of compounds were recorded at
25 C with an Agilent 400 MR DD2 (400 MHz) spectrometer.
Chemical shift (d) values in delta parts per million (ppm) were
determined using CDCl3 as a solvent. Multiplicities were
expressed as a singlet (s), doublet (d), triplet (t), quartet (q),
quintet (quint), sextet (sex), septet (sep), doublet of doublets
(dd), triplet of doublets (td), doublet of triplets (dt), or
multiplet (m). Coupling constants (J) were expressed in Hz.
High-resolution mass spectra were determined by Finnigan
MAT-95XL high-resolution electron impact ionization. A sin-
gle crystal of compound 4c was selected for X-ray diffractom-
etry, and data were acquired by a crystallographic assay using
a Bruker Kappa CCD diffractometer, employing graphite-
monochromated Mo Ka radiation at 200 K and the qe2q scanPlease cite this article in press as: Chen, C.-L. et al., Synthesis and evaluation of ne
agents. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015mode. The space group for compound 4c was analyzed on the
basis of intensity statistics and systematic absences. The struc-
ture of compound 4c was resolved by direct methods using
SIR92 or SIR97 and refined with SHELXL-97. The purity of
these thioxanthone derivatives was determined on a C18
reverse-phase column (XBridge BEH Shield RP18 Column,
130 A˚, 5 lm, 4.6 mm  250 mm, Waters) by HPLC (model
l-2000, HITACHI) with UV detection (model l-2400, HITA-
CHI). Thioxanthone derivative (1 mg) was dissolved in metha-
nol (20 mL) and analyzed by HPLC. The mobile phase was
MeOH/water. A preliminary evaluation of the UV absorbance
and kmax for each compound was determined by spectrophoto-
metric analysis. The purity of these thioxanthone derivatives
was greater than 95%.w 3-substituted-4-chloro-thioxanthone derivatives as potent anti-breast cancer
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4 C.-L. Chen et al.2.2. Synthesis of target compounds 3, 4a–4s and 5a–5s
2.2.1. Synthetic procedure i: preparation of 2-((2,3-
dichlorophenyl)thio)benzoic acid (3)
At room temperature, an aqueous solution of 1 M KOH
(10 mL) was added dropwise with stirring to a solution of
2,3-dichlorothiophenol (1) (0.9 g, 5 mmol) in DMF (10 mL).
After 10 min, the mixture was treated with 2-iodobenzoic acid
(2) (1.24 g, 5 mmol) in DMF (10 mL) using copper powder
(0.315 g) as a catalyst with stirring at 120 C for 8 h. The mix-
ture was filtered while hot, and the filtrate was acidified with
1 M HCl(aq) (10 mL) to precipitate the crude product. The
crude product was collected, washed with water, and dried in
vacuo to get the desired 2-((2,3-dichlorophenyl)thio)benzoic
acid (3) (Jı´lek et al., 1981).
2.2.2. Synthetic procedure ii: preparation of compound 4a
2-((2,3-Dichlorophenyl)thio)benzoic acid (3) (0.3 g, 1 mmol)
was added to a 75% H2SO4 solution (10 mL) at 0 C in a mini-
clave, then mixture was heated to 110 C for 6 h. After cooling,
the reaction mixture was poured into ice water (200 mL), and
the precipitate was obtained after 20 min. The precipitate was
dissolved in dichloromethane, extracted with dichloro-
methane/water system, and dried over MgSO4. The solvent
was removed in vacuo obtaining 4a as an off-white powder.
2.2.3. General procedure iii: preparation of compounds 4b–4s
To a mixture of sodium methoxide (0.108 g, 2 mmol) in metha-
nol (10 mL), the substituted-benzenethiol derivative (2 mmol)
was added with stirring for 15 min. Compound 4a in tetrahy-
drofuran (10 mL) was added to the reaction mixture, which
was then refluxed for 2 h. The mixture was filtered while hot,
and the filtrate was collected and concentrated in vacuo. Then,
it was extracted with dichloromethane, and the organic layer
was dried over MgSO4 and the solvent was removed under
reduced pressure. The product obtained was recrystallized
from ethanol.
2.2.4. Synthetic procedure iv: preparation of compound 5a
A solution of compound 4a (0.313 g, 1 mmol) in acetic acid
(20 mL) was treated with 30% hydrogen peroxide (10 mL),
warmed slowly for 1 h at 45 C, and then refluxed for 2 h. A
slight exothermic reaction was noted during the early heating.
After cooling, the reaction was diluted with 200 mL of ice
water. The resulting solid was removed by filtration, washed
with water, and dried, yielding the pale-yellow solid
compound.
2.2.5. General procedure v: preparation of compounds 5b–5s
To a mixture of sodium methoxide (0.108 g, 2 mmol) in metha-
nol (10 mL), the substituted-benzenethiol derivative (1 mmol)
was added with stirring for 15 min. Compound 5a in tetrahy-
drofuran (20 mL) was added to the reaction mixture, and
refluxed for 2 h. The mixture was filtered while hot, and the fil-
trate was collected and concentrated in vacuo. Then, it was
extracted with dichloromethane, the organic layer was dried
over MgSO4, and the solvent was removed under reduced pres-
sure. The product obtained was recrystallized from ethanol.Please cite this article in press as: Chen, C.-L. et al., Synthesis and evaluation of n
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2.3.1. 3,4-Dichloro-9H-thioxanthen-9-one (4a)
The pure compound was obtained as an off-white powder
(yield 60%). Mp 194–195 C. 1H NMR (400 MHz, CDCl3):
d ppm 7.52–7.56 (m, 1H), 7.59 (d, J= 8.8 Hz, 1H), 7.65–
7.71 (m, 2H), 8.52 (d, J= 8.4 Hz, 1H), 8.58 (dd, J= 7.6 Hz,
J= 1.2 Hz, 1H). 13C NMR (100 MHz, CDCl3): d ppm
126.51, 127.16, 127.36, 127.96, 128.10, 129.13, 129.23, 129.81,
132.89, 136.62, 137.80, 138.58, 179.28. HRMS-EI m/z calcd
for [M]+: 279.9516, found: 279.9514.
2.3.2. 4-Chloro-3-(phenylthio)-9H-thioxanthen-9-one (4b)
The pure compound was obtained as a pale-yellow powder
(yield 34%). Mp 180–181 C. 1H NMR (400 MHz, CDCl3):
d ppm 6.79 (d, J= 8.8 Hz, 1H), 7.49–7.53 (m, 4H), 7.59–
7.62 (m, 2H), 7.65–7.66 (m, 2H), 8.33 (d, J= 8.4 Hz, 1H),
8.54–8.56 (m, 1H). 13C NMR (100 MHz, CDCl3): d ppm
123.73, 124.83, 126.51, 126.85, 127.67, 128.14, 128.28, 129.44,
129.69, 130.10, 130.17, 132.58, 135.67, 136.57, 137.37, 145.33,
179.38. HRMS-EI m/z calcd for [M]+: 353.9940, found:
353.9943.
2.3.3. 4-Chloro-3-(o-tolylthio)-9H-thioxanthen-9-one (4c)
The pure compound was obtained as pale-yellow crystals
(yield 41%). Mp 208–210 C. 1H NMR (400 MHz, CDCl3):
d ppm 2.39 (s, 3H), 6.60 (d, J= 8.8 Hz, 1H), 7.32 (td,
J= 7.2 Hz, J= 2.4 Hz, 1H), 7.41–7.52 (m, 3H), 7.59–7.66
(m, 3H), 8.30 (d, J= 8.8 Hz, 1H), 8.55 (d, J= 8.0 Hz, 1H).
13C NMR (100 MHz, CDCl3): d ppm 20.68, 122.88, 124.70,
126.50, 126.82, 127.48, 127.61, 128.17, 128.27, 128.32, 129.67,
130.83, 131.45, 132.55, 136.54, 137.11, 137.39, 143.35, 144.72,
179.38. HRMS-EI m/z calcd for [M]+: 368.0096, found:
368.0092.
2.3.4. 4-Chloro-3-(m-tolylthio)-9H-thioxanthen-9-one (4d)
The pure compound was obtained as a pale-yellow powder
(yield 38%). Mp 169–170 C. 1H NMR (400 MHz, CDCl3):
d ppm 2.41 (s, 3H), 6.79 (d, J= 8.8 Hz, 1H), 7.31–7.33 (m,
1H), 7.36–7.42 (m, 3H), 7.47–7.51 (m, 1H), 7.63–7.64 (m,
2H), 8.31 (d, J= 8.8 Hz, 1H), 8.54 (dt, J= 7.6 Hz,
J= 0.8 Hz, 1H). 13C NMR (100 MHz, CDCl3): d ppm
21.94, 123.68, 124.61, 126.47, 126.79, 127.50, 128.05, 128.23,
128.97, 129.63, 129.94, 130.94, 132.51, 132.69, 136.17, 136.53,
137.25, 140.19, 145.57, 179.32. HRMS-EI m/z calcd for
[M]+: 368.0096, found: 368.0095.
2.3.5. 4-Chloro-3-(p-tolylthio)-9H-thioxanthen-9-one (4e)
The pure compound was obtained as a pale-yellow powder
(yield 51%). Mp 203–204 C. 1H NMR (400 MHz, CDCl3):
d ppm 2.45 (s, 3H), 6.75 (d, J= 8.8 Hz, 1H), 7.31 (d,
J= 8.0 Hz, 2H), 7.48–7.52 (m, 3H), 7.64–7.66 (m, 2H), 8.31
(d, J= 8.4 Hz, 1H), 8.55 (dt, J= 7.6 Hz, J= 1.0 Hz, 1H).
13C NMR (100 MHz, CDCl3): d ppm 21.41, 123.39, 124.38,
125.52, 126.50, 126.80, 127.42, 128.05, 128.27, 129.65,
131.00, 132.53, 135.84, 136.55, 137.26, 140.64, 145.97,
179.38. HRMS-EI m/z calcd for [M]+: 368.0096, found:
368.0100.ew 3-substituted-4-chloro-thioxanthone derivatives as potent anti-breast cancer
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Synthesis and evaluation of 3-substituted-4-chloro-thioxanthone derivatives 52.3.6. 4-Chloro-3-(4-chlorophenylthio)-9H-thioxanthen-9-one
(4f)
The pure compound was obtained as a pale-yellow powder
(yield 47%). Mp:223–224 C. 1H NMR (400 MHz, CDCl3): d
ppm 6.80 (d, J= 8.8 Hz, 1H), 7.46–7.55 (m, 5H), 7.64–7.67
(m, 2H), 8.35 (d, J= 8.8 Hz, 1H), 8.55 (d, J= 8.0 Hz 1H).
13C NMR (100 MHz, CDCl3): d ppm 123.71, 125.13, 126.51,
126.92, 127.88, 128.03, 128.21, 128.26, 129.70, 130.43, 132.65,
136.48, 136.57, 136.76, 137.51, 144.44, 179.32. HRMS-EI m/z
calcd for [M]+: 387.9550, found: 387.9511.
2.3.7. 4-Chloro-3-(3-chlorophenylthio)-9H-thioxanthen-9-one
(4g)
The pure compound was obtained as a pale-yellow powder
(yield 55%). Mp:181–182 C. 1H NMR (400 MHz, CDCl3): d
ppm 6.86 (d, J= 8.8 Hz, 1H), 7.41–7.54 (m, 4H), 7.59 (t,
J= 1.6 Hz, 1H), 7.64–7.67 (m, 2H), 8.37 (d, J= 8.8 Hz,
1H), 8.56 (d, J= 8.0 Hz, 1H). 13C NMR (100 MHz, CDCl3):
d ppm 124.20, 125.57, 126.52, 126.94, 128.10, 128.21, 128.34,
129.72, 130.17, 131.11, 131.72, 132.67, 133.25, 134.81, 135.66,
136.50, 137.57, 143.84, 179.33. HRMS-EI m/z calcd for
[M]+: 387.9550, found: 387.9551.
2.3.8. 3-(4-Bromophenylthio)-4-chloro-9H-thioxanthen-9-one
(4h)
The pure compound was obtained as a pale-yellow powder
(yield 48%). Mp 222–223 C. 1H NMR (400 MHz, CDCl3):
d ppm 6.83 (d, J= 8.8 Hz, 1H), 7.45 (dt, J= 6.8 Hz,
J= 1.9 Hz, 2H), 7.49–7.53 (m, 1H), 7.61–7.67 (m, 4H), 8.35
(d, J= 8.8 Hz, 1H), 8.54–8.57 (m, 1H). 13C NMR
(100 MHz, CDCl3): d ppm 123.88, 124.75, 125.31, 126.52,
126.93, 127.98, 128.25, 128.29, 128.82, 129.72, 132.66, 133.39,
136.50, 136.87, 137.54, 144.22, 179.32. HRMS-EI m/z calcd
for [M]+: 431.9045, found: 431.9037.
2.3.9. 4-Chloro-3-(2,4-dimethylphenylthio)-9H-thioxanthen-9-
one (4i)
The pure compound was obtained as a pale-yellow powder
(yield 28%). Mp 172–173 C. 1H NMR (400 MHz, CDCl3):
d ppm 2.34 (s, 3H), 2.41 (s, 3H), 6.60 (d, J= 8.8 Hz, 1H),
7.13 (d, J= 8.0 Hz, 1H), 7.24 (s, 1H), 7.47–7.51 (m, 2H),
7.64–7.65 (m, 2H), 8.29 (d, J= 8.8 Hz, 1H), 8.54 (d,
J= 8.0 Hz, 1H). 13C NMR (100 MHz, CDCl3): d ppm
20.56, 21.31, 122.74, 124.48, 124.69, 126.49, 126.79, 127.36,
128.10, 128.31, 128.43, 129.65, 132.32, 132.50, 136.56, 137.12,
137.33, 141.24, 143.17, 145.24, 179.38. HRMS-EI m/z calcd
for [M]+: 382.0253, found: 382.0258.
2.3.10. 4-Chloro-3-(2,6-dimethylphenylthio)-9H-thioxanthen-9-
one (4j)
The pure compound was obtained as a pale-yellow powder
(yield 30%). Mp 215–216 C. 1H NMR (400 MHz, CDCl3):
d ppm 2.42 (s, 6H), 6.49 (d, J= 8.4 Hz, 1H), 7.25–7.27 (m,
2H), 7.33–7.36 (m, 1H), 7.48–7.52 (m, 1H), 7.65–7.66 (m,
2H), 8.28 (d, J= 8.4 Hz, 1H), 8.55 (d, J= 8.0 Hz, 1H). 13C
NMR (100 MHz, CDCl3): d ppm 21.63, 121.95, 124.85,
126.50, 126.80, 127.36, 127.81, 128.27, 128.32, 128.99, 129.67,
130.49, 132.52, 136.54, 137.44, 144.29, 144.31, 179.38.
HRMS-EI m/z calcd for [M]+: 382.0253, found: 382.0259.Please cite this article in press as: Chen, C.-L. et al., Synthesis and evaluation of ne
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one (4k)
The pure compound was obtained as pale-yellow crystals
(yield 46%). Mp 183–184 C. 1H NMR (400 MHz, CDCl3):
d ppm 2.37 (s, 6H), 6.81 (d, J= 8.8 Hz, 1H), 7.13 (s, 1H),
7.22 (s, 2H) 7.48–7.52 (m, 1H), 7.64–7.65 (m, 2H), 8.32 (d,
J= 8.8 Hz, 1H), 8.55 (d, J= 8.0 Hz, 1H). 13C NMR
(100 MHz, CDCl3): d ppm 21.18, 123.79, 124.57, 126.50,
126.80, 127.48, 128.05, 128.30, 128.65, 129.66, 131.92, 132.52,
133.23, 136.60, 137.23, 139.95, 145.85, 179.39. HRMS-EI m/z
calcd for [M]+: 382.0253, found: 382.0249.
2.3.12. 4-Chloro-3-(2-methoxylphenylthio)-9H-thioxanthen-9-
one (4l)
The pure compound was obtained as a pale-yellow powder
(yield 58%). Mp 181–183 C. 1H NMR (400 MHz, CDCl3):
d ppm 3.82 (s, 3H), 6.71 (d, J= 8.8 Hz, 1H), 7.05–7.09 (m,
2H), 7.48–7.55 (m, 2H), 7.58 (dd, J= 7.6 Hz, J= 1.6 Hz,
1H), 7.64–7.65 (m, 2H), 8.31 (d, J= 8.8 Hz, 1H), 8.55 (d,
J= 8.0 Hz, 1H). 13C NMR (100 MHz, CDCl3): d ppm
55.98, 111.82, 116.72, 121.77, 123.31, 124.75, 126.49, 126.75,
127.47, 127.84, 128.31, 129.64, 132.42, 132.48, 136.63, 137.20,
137.58, 144.52, 160.18, 179.44. HRMS-EI m/z calcd for
[M]+: 384.0045, found: 384.0038.
2.3.13. 4-Chloro-3-(3-methoxylphenylthio)-9H-thioxanthen-9-
one (4m)
The pure compound was obtained as a pale-yellow powder
(yield 44%). Mp 208–209 C. 1H NMR (400 MHz, CDCl3):
d ppm 3.84 (s, 3H), 6.85 (d, J= 8.5 Hz, 1H), 7.03–7.06 (m,
1H), 7.13 (t, J= 2.0 Hz, 1H), 7.17–7.20 (m, 1H), 7.41 (t,
J= 8.0 Hz, 1H), 7.49–7.53 (m, 1H), 7.65–7.66 (m, 2H), 8.34
(d, J= 8.8 Hz, 1H), 8.55 (dt, J= 8.4 Hz, J= 1.0 Hz, 1H).
13C NMR (100 MHz, CDCl3): d ppm 55.47, 116.21, 120.36,
123.78, 124.75, 126.50, 126.84, 127.63, 127.72, 128.14, 128.23,
129.66, 130.28, 130.94, 132.57, 136.53, 137.31, 145.20, 160.58,
179.35. HRMS-EI m/z calcd for [M]+: 384.0045, found:
384.0045.
2.3.14. 4-Chloro-3-(4-methoxylphenylthio)-9H-thioxanthen-9-
one (4n)
The pure compound was obtained as a pale-yellow powder
(yield 65%). Mp 163–165 C. 1H NMR (400 MHz, CDCl3):
d ppm 3.89 (s, 3H), 6.72 (d, J= 8.8 Hz, 1H), 7.03 (dt,
J= 9.6 Hz, J= 2.6 Hz, 2H), 7.48–7.55 (m, 3H), 7.64–7.65
(m, 2H), 8.31 (d, J= 8.8 Hz, 1H), 8.54 (dt, J= 8.0 Hz,
J= 1.0 Hz, 1H). 13C- R (100 MHz, CDCl3): d ppm 55.48,
115.79, 119.32, 123.10, 124.06, 126.50, 126.79, 127.36, 128.04,
128.31, 129.66, 132.51, 136.55, 137.23, 137.72, 146.49, 161.34,
179.37. HRMS-EI m/z calcd for [M]+: 384.0045, found:
384.0046.
2.3.15. 4-Chloro-3-(2-ethylphenylthio)-9H-thioxanthen-9-one
(4o)
The pure compound was obtained as a pale-yellow powder
(yield 61%). Mp 165–166 C. 1H NMR (400 MHz, CDCl3):
d ppm 1.20 (t, J= 7.6 Hz, 3H), 2.78 (q, J= 7.6 Hz, 2H),
6.61 (d, J= 8.8 Hz, 1H), 7.32 (td, J= 7.4 Hz, J= 1.5 Hz,
1H), 7.44–7.52 (m, 3H), 7.57 (dd, J= 7.8 Hz, J= 1.0 Hz,w 3-substituted-4-chloro-thioxanthone derivatives as potent anti-breast cancer
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J= 8.0, 1H). 13C NMR (100 MHz, CDCl3): d ppm 15.27,
27.31, 123.17, 124.59, 126.50, 126.82, 127.44, 127.61, 127.80,
128.12, 128.31, 129.67, 129.94, 131.02, 132.54, 136.56, 137.32,
137.43, 145.49, 149.11, 179.39. HRMS-EI m/z calcd for
[M]+: 382.0253, found: 382.0252.
2.3.16. 4-Chloro-3-(3-ethoxylphenylthio)-9H-thioxanthen-9-
one (4p)
The pure compound was obtained as a pale-yellow powder
(yield 63%). Mp 149–150 C. 1H NMR (400 MHz, CDCl3):
d ppm 1.43 (t, J= 7.0 Hz, 3H), 4.05 (q, J= 7.1 Hz, 2H),
6.85 (d, J= 8.8 Hz, 1H), 7.02–7.05 (m, 1H), 7.11 (t,
J= 2.0 Hz, 1H), 7.17 (d, J= 7.6 Hz, 1H), 7.39 (t,
J= 8.0 Hz, 1H), 7.49–7.53 (m, 1H), 7.65–7.67 (m, 2H), 8.34
(d, J= 8.8 Hz, 1H), 8.55 (d, J= 8.0 Hz, 1H). 13C NMR
(100 MHz, CDCl3): d ppm 14.70, 63.77, 116.74, 120.89,
123.87, 124.81, 126.51, 126.84, 127.53, 127.67, 128.14, 128.29,
129.69, 130.27, 130.92, 132.56, 136.57, 137.32, 145.29, 160.01,
179.37. HRMS-EI m/z calcd for [M]+: 398.0202, found:
398.0204.
2.3.17. 4-Chloro-3-(4-isopropylphenylthio)-9H-thioxanthen-9-
one (4q)
The pure compound was obtained as a pale-yellow powder
(yield 71%). Mp 160–161 C. 1H NMR (400 MHz, CDCl3):
d ppm 1.31 (d, J= 7.2 Hz, 6H), 3.00 (sep, J= 6.9 Hz, 1H),
6.78 (d, J= 8.8 Hz, 1H), 7.36 (d, J= 8.4 Hz, 2H), 7.47–7.53
(m, 3H), 7.64–7.65 (m, 2H), 8.32 (d, J= 8.8 Hz, 1H), 8.54
(d, J= 8.0 Hz, 1H). 13C NMR (100 MHz, CDCl3): d ppm
23.81, 34.01, 123.48, 124.40, 125.83, 126.49, 126.79, 127.45,
128.06, 128.29, 128.38, 129.65, 132.51, 135.87, 136.57, 137.25,
145.94, 151.40, 179.36. HRMS-EI m/z calcd for [M]+:
396.0409, found: 396.0409.
2.3.18. 4-Chloro-3-(2-isopropylphenylthio)-9H-thioxanthen-9-
one (4r)
The pure compound was obtained as pale-yellow crystals
(yield 59%). Mp 152–153 C. 1H NMR (400 MHz, CDCl3):
d ppm 1.20 (d, J= 6.8 Hz, 6H), 3.47 (sep, J= 6.9 Hz, 1H),
6.61 (d, J= 8.8 Hz, 1H), 7.28–7.32 (m, 1H), 7.47–7.55 (m,
3H), 7.57 (d, J= 7.6 Hz, 1H), 7.63–7.64 (m, 2H), 8.29 (d,
J= 8.8 Hz, 1H), 8.53 (d, J= 8.0 Hz, 1H). 13C NMR
(100 MHz, CDCl3): d ppm 23.82, 31.06, 123.18, 124.42,
126.46, 126.77, 127.15, 127.22, 127.36, 127.43, 128.05, 128.26,
129.63, 131.22, 132.49, 136.50, 137.27, 137.41, 145.77, 153.55,
179.32. HRMS-EI m/z calcd for [M]+: 396.0409, found:
396.0404.
2.3.19. 3-(Benzylthio)-4-chloro-9H-thioxanthen-9-one (4s)
The pure compound was obtained as a pale-yellow powder
(yield 41%). Mp 196–197 C. 1H NMR (400 MHz, CDCl3):
d ppm 4.31 (s, 2H), 7.30–7.38 (m, 4H), 7.43–7.45 (m, 2H),
7.49–7.53 (m, 1H), 7.63–7.66 (m, 2H), 8.48 (d, J= 8.4 Hz,
1H), 8.57 (d, J= 7.6 Hz, 1H). 13C NMR (100 MHz, CDCl3):
d ppm 36.67, 122.79, 125.69, 126.49, 126.83, 127.48, 127.89,
128.25, 128.29, 128.87, 128.90, 129.69, 132.60, 134.90, 136.61,
137.30, 143.84, 179.45. HRMS-EI m/z calcd for [M]+:
368.0096, found: 368.0097.Please cite this article in press as: Chen, C.-L. et al., Synthesis and evaluation of n
agents. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.20152.3.20. 3,4-Dichloro-9H-thioxanthen-9-one-10,10-dioxide (5a)
The pure compound was obtained as a pale-yellow powder
(yield 33%). Mp 233–235 C. 1H NMR (400 MHz, CDCl3):
d ppm 7.82 (td, J= 7.6 Hz, J= 0.9 Hz, 1H), 7.86 (d,
J= 8.4 Hz, 1H), 7.94 (td, J= 7.7 Hz, J= 1.2 Hz, 1H), 8.19
(dd, J= 7.8 Hz, J= 0.6 Hz, 1H), 8.31 (d, J= 8.8 Hz, 1H),
8.36 (dd, J= 7.8 Hz, J= 1.0 Hz, 1H). 13C NMR (100 MHz,
CDCl3): d ppm 123.87, 128.46, 128.68, 128.76, 130.08,
130.24, 133.29, 133.93, 135.52, 139.52, 142.07, 142.21, 176.42.
HRMS-EI m/z calcd for [M]+: 311.9415, found: 311.9408.
2.3.21. 4-Chloro-3-(benzenethio)-9H-thioxanthen-9-one 10,10-
dioxide (5b)
The pure compound was obtained as a pale-yellow powder
(yield 31%). Mp 241–242 C. 1H NMR (400 MHz, CDCl3):
d ppm 6.94 (d, J= 8.4 Hz, 1H), 7.51–7.61 (m, 5H), 7.78 (td,
J= 7.6 Hz, J= 1.1 Hz, 1H), 7.91 (td, J= 7.7 Hz,
J= 1.2 Hz, 1H), 8.08 (d, J= 8.4 Hz, 1H), 8.19 (dd,
J= 8.0 Hz, J= 0.4 Hz, 1H), 8.32 (dd, J= 7.8 Hz, 1.0 Hz,
1H). 13C NMR (100 MHz, CDCl3): d ppm 123.73, 126.22,
127.74, 127.94, 128.43, 128.53, 128.75, 128.97, 130.54, 130.70,
133.08, 135.17, 136.00, 137.96, 142.22, 151.39, 176.58.
HRMS-EI m/z calcd for [M]+: 385.9838, found: 385.9837.
2.3.22. 3-(2-Methylbenzenethio)-4-chloro-9H-thioxanthen-9-
one 10,10-dioxide (5c)
The pure compound was obtained as a pale-yellow powder
(yield 57%). Mp 254–255 C. 1H NMR (400 MHz, CDCl3):
d ppm 2.37 (s, 3H), 6.77 (d, J= 8.4 Hz, 1H), 7.32–7.37 (m,
1H), 7.43–7.50 (m, 2H), 7.59 (d, J= 7.6 Hz, 1H), 7.78 (td,
J= 7.7 Hz, J= 0.9 Hz, 1H), 7.91 (td, J= 7.7 Hz,
J= 1.3 Hz, 1H), 8.07 (d, J= 8.4 Hz, 1H), 8.19 (dd,
J= 8.0 Hz, J= 0.4 Hz, 1H), 8.32 (dd, J= 8.0 Hz,
J= 0.8 Hz, 1H). 13C NMR (100 MHz, CDCl3): d ppm
20.57, 123.72, 126.37, 127.45, 127.81, 127.83, 127.95, 128.23,
128.52, 128.77, 131.33, 131.70, 133.07, 135.14, 137.23, 138.03,
142.20, 143.50, 150.49, 176.59. HRMS-EI m/z calcd for
[M]+: 399.9995, found: 399.9987.
2.3.23. 3-(3-Methylbenzenethio)-4-chloro-9H-thioxanthen-9-
one 10,10-dioxide (5d)
The pure compound was obtained as a pale-yellow powder
(yield 57%). Mp 247–249 C. 1H NMR (400 MHz, CDCl3):
d ppm 2.42 (s, 3H), 6.96 (d, J= 8.8 Hz, 1H), 7.35–7.44 (m,
4H), 7.78 (t, J = 7.6 Hz, 1H), 7.91 (t, J = 7.4 Hz, 1H), 8.08
(d, J = 8.4 Hz, 1H), 8.18 (d, J = 8.0 Hz, 1H), 8.32 (d,
J = 7.6 Hz 1H). 13C NMR (100 MHz, CDCl3): d ppm 21.31,
123.73, 126.14, 127.71, 127.85, 128.06, 128.52, 128.77, 129.05,
130.32, 131.53, 132.96, 133.07, 135.15, 136.43, 137.90, 140.66,
142.23, 151.65, 176.61. HRMS-EI m/z calcd for [M]+:
399.9995, found: 399.9989.
2.3.24. 4-Chloro-3-(4-methylbenzenethio)9H-thioxanthen-9-one
10,10-dioxide (5e)
The pure compound was obtained as a pale-yellow powder
(yield 72%). Mp 246–247 C. 1H NMR (400 MHz, CDCl3):
d ppm 2.46 (s, 3H), 6.93 (d, J= 8.8 Hz, 1H), 7.34 (d,
J= 8.0 Hz, 2H), 7.47 (d, J= 7.6 Hz, 2H), 7.78 (t,
J= 7.6 Hz, 1H), 7.91 (t, J= 7.6 Hz, 1H), 8.07 (d,ew 3-substituted-4-chloro-thioxanthone derivatives as potent anti-breast cancer
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J= 8.0 Hz, 1H). 13C NMR (100 MHz, CDCl3): d ppm
21.43, 123.71, 124.67, 126.02, 127.66, 127.77, 128.50, 128.75,
128.82, 131.33, 133.05, 135.13, 135.96, 137.86, 141.25, 142.21,
151.91, 176.60. HRMS-EI m/z calcd for [M]+: 399.9995,
found: 399.9990.
2.3.25. 4-Chloro-3-(4-chlorobenzenethio)-9H-thioxanthen-9-
one 10,10-dioxide (5f)
The pure compound was obtained as a pale-yellow powder
(yield 57%). Mp 249–251 C. 1H NMR (400 MHz, CDCl3):
d ppm 6.96 (d, J= 8.4 Hz, 1H), 7.50–7.55 (m, 4H), 7.79 (t,
J= 7.6 Hz, 1H), 7.92 (t, J= 7.2 Hz, 1H), 8.11 (d,
J= 8.4 Hz, 1H), 8.19 (d, J= 8.0 Hz, 1H), 8.33 (d,
J= 8.0 Hz, 1H). 13C NMR (100 MHz, CDCl3): d ppm
123.75, 126.45, 126.95, 127.86, 128.21, 128.58, 128.71, 128.94,
129.30, 130.84, 133.14, 135.24, 137.20, 137.36, 142.18, 150.55,
176.54. HRMS-EI m/z calcd for [M]+: 419.9448, found:
419.9447.
2.3.26. 3-(3-Chlorophenylthio)-4-chloro-9H-thioxanthen-9-one
10,10-dioxide (5g)
The pure compound was obtained as a pale-yellow powder
(yield 57%). Mp 262–263 C. 1H NMR (400 MHz, CDCl3):
d ppm 7.00 (d, J= 8.8 Hz, 1H), 7.47–7.55 (m, 3H),
7.60–7.61 (m, 1H), 7.79 (td, J= 8.2 Hz, 1.2 Hz, 1H), 7.92
(td, J= 7.6 Hz, J= 1.2 Hz, 1H), 8.33 (d, J= 8.8 Hz, 1H),
8.19 (d, J= 8.0 Hz, 1H), 8.33 (dd, J= 8.0 Hz, J= 0.8 Hz,
1H). 13C NMR (100 MHz, CDCl3): d ppm 123.76, 126.66,
127.94, 128.40, 128.59, 128.74, 129.25, 130.53, 130.91, 131.51,
133.13, 133.86, 135.23, 135.44, 136.06, 138.19, 142.23, 150.09,
176.54. HRMS-EI m/z calcd for [M]+: 419.9448, found:
419.9450.
2.3.27. 3-(4-Bromobenzenethio)-4-chloro-9H-thioxanthen-9-
one 10,10-dioxide (5h)
The pure compound was obtained as a pale-yellow powder
(yield 80%). Mp 256–258 C. 1H NMR (400 MHz, CDCl3):
d ppm 6.97 (d, J= 8.4 Hz, 1H), 7.46 (d, J= 8.4 Hz, 2H),
7.67 (d, J= 8.0 Hz, 2H), 7.79 (t, J= 7.6 Hz, 1H), 7.92 (t,
J= 7.4 Hz, 1H), 8.11 (d, J= 8.8 Hz, 1H), 8.18 (d,
J= 7.6 Hz, 1H), 8.33 (d, J= 8.0 Hz, 1H). 13C NMR
(100 MHz, CDCl3): d ppm 123.75, 125.59, 126.53, 127.67,
127.87, 128.28, 128.58, 128.74, 129.02, 133.12, 133.80, 135.22,
137.34, 138.16, 142.22, 150.36, 176.53. HRMS-EI m/z calcd
for [M]+: 463.8943, found: 463.8941.
2.3.28. 4-Chloro-3-(2,4-dimethylbenzenethio) 9H-thioxanthen-
9-one 10,10-dioxide (5i)
The pure compound was obtained as a pale-yellow powder
(yield 70%). Mp 235–236 C. 1H NMR (400 MHz, CDCl3):
d ppm 2.33 (s, 3H), 2.42 (s, 3H), 6.77 (d, J= 8.8 Hz, 1H),
7.15 (d, J= 7.6 Hz, 1H), 7.45 (d, J= 7.6 Hz, 1H), 7.56–7.95
(m, 3H), 8.06 (d, J= 8.4 Hz, 1H), 8.18 (d, J= 8.0 Hz, 1H),
8.32 (d, J= 7.6 Hz, 1H). 13C NMR (100 MHz, CDCl3): d
ppm 20.44, 21.33, 123.72, 123.86, 123.89, 127.74, 128.18,
128.50, 128.68, 128.76, 128.81, 132.55, 133.04, 135.10, 135.52,
137.12, 141.80, 142.25, 143.23, 150.99, 176.63. HRMS-EI m/z
calcd for [M]+: 414.0151, found: 414.0155.Please cite this article in press as: Chen, C.-L. et al., Synthesis and evaluation of ne
agents. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.20152.3.29. 4-Chloro-3-(2,6-dimethylbenzenethio)-9H-thioxanthen-
9-one 10,10-dioxide (5j)
The pure compound was obtained as a pale-yellow powder
(yield 81%). Mp 285–286 C. 1H NMR (400 MHz, CDCl3):
d ppm 2.39 (s, 6H), 6.77 (d, J= 8.8 Hz, 1H), 7.28 (d,
J= 7.6 Hz, 2H), 7.34–7.36 (m, 1H), 7.78 (td, J = 7.6 Hz,
J = 0.9 Hz, 1H), 7.91 (td, J= 7.7 Hz, J = 1.2 Hz, 1H), 8.06
(d, J= 8.8 Hz, 1H), 8.19 (dd, J= 8.0 Hz, J = 0.8 Hz, 1H),
8.32 (dd, J= 7.2 Hz, J= 1.0 Hz 1H). 13C NMR (100 MHz,
CDCl3): d ppm 21.49, 123.72, 127.42, 127.72, 127.93, 128.51,
128.69, 128.77, 128.81, 129.23, 130.90, 133.07, 135.11, 135.52,
142.21, 144.26, 149.84, 176.61. HRMS-EI m/z calcd for
[M]+: 414.0151, found: 414.0154.
2.3.30. 4-Chloro-3-(3,5-dimethylbenzenethio)9H-thioxanthen-
9-one 10,10-dioxide (5k)
The pure compound was obtained as a pale-yellow powder
(yield 69%). Mp 275–276 C. 1H NMR (400 MHz, CDCl3):
d ppm 2.38 (s, 6H), 6.98 (d, J= 8.4 Hz, 1H), 7.17 (s, 1H),
7.20 (s, 2H), 7.78 (t, J= 7.4 Hz, 1H), 7.91 (td, J= 7.6 Hz,
J= 0.8 Hz, 1H), 8.08 (d, J= 8.8 Hz, 1H), 8.18 (d,
J= 8.0 Hz, 1H), 8.32 (d, J= 7.6 Hz, 1H). 13C NMR
(100 MHz, CDCl3): d ppm 21.18, 123.72, 126.09, 127.67,
127.75, 127.79, 128.50, 128.80, 129.13, 132.45, 133.03, 133.41,
135.11, 137.88, 140.38, 142.27, 151.87, 177.63. HRMS-EI m/z
calcd for [M]+: 414.0151, found: 414.0151.
2.3.31. 4-Chloro-3-(2-methoxyphenylthio)-9H-thioxanthen-9-
one 10,10-dioxide (5l)
The pure compound was obtained as a pale-yellow powder
(yield 44%). Mp 274–276 C. 1H NMR (400 MHz, CDCl3):
d ppm 3.82 (s, 3H), 6.87 (d, J= 8.8 Hz, 1H), 7.06–7.11 (m,
2H), 7.54–7.59 (m, 2H), 7.78 (t, J= 7.4 Hz, 1H), 7.91 (t,
J= 7.4 Hz, 1H), 8.07 (d, J= 8.8 Hz, 1H), 8.18 (d,
J= 8.0 Hz, 1H), 8.32 (d, J= 8.0 Hz, 1H). 13C NMR
(100 MHz, CDCl3): d ppm 55.98, 111.95, 115.74, 121.98,
123.72, 126.32, 127.42, 127.75, 128.48, 128.67, 128.85, 133.00,
135.08, 137.76, 137.84, 142.28, 150.30, 160.18, 176.72.
HRMS-EI m/z calcd for [M]+: 415.9944, found: 415.9947.
2.3.32. 4-Chloro-3-(3-methoxyphenylthio)-9H-thioxanthen-9-
one 10,10-dioxide (5m)
The pure compound was obtained as a pale-yellow powder
(yield 58%). Mp 231–233 C. 1H NMR (400 MHz, CDCl3):
d ppm 3.84 (s, 3H), 7.00 (d, J= 8.4 Hz, 1H), 7.08–7.12 (m,
2H), 7.18 (d, J= 7.6 Hz, 1H), 7.44 (t, J= 8.0 Hz, 1H), 7.78
(t, J= 7.8 Hz, 1H), 7.91 (t, J= 7.4 Hz, 1H), 8.10 (d,
J= 8.4 Hz, 1H), 8.18 (d, J= 8.0 Hz, 1H), 8.33 (d,
J= 8.0 Hz, 1H). 13C NMR (100 MHz, CDCl3): d ppm
55.53, 116.81, 120.62, 123.73, 126.23, 127.76, 127.97, 128.00,
128.54, 128.79, 129.14, 129.38, 131.32, 133.07, 135.15, 137.98,
142.25, 151.30, 160.89, 176.60. HRMS-EI m/z calcd for
[M]+: 415.9944, found: 415.9939.
2.3.33. 4-Chloro-3-(4-methoxyphenylthio)-9H-thioxanthen-9-
one 10,10-dioxide (5n)
The pure compound was obtained as a pale-yellow powder
(yield 58%). Mp 263–265 C. 1H NMR (400 MHz, CDCl3):
d ppm 3.89 (s, 3H), 6.92 (d, J = 8.4 Hz, 1H), 7.03–7.07 (m,w 3-substituted-4-chloro-thioxanthone derivatives as potent anti-breast cancer
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7.91 (td, J = 7.7 Hz, J = 1.0 Hz, 1H), 8.08 (d, J = 8.8 Hz,
1H), 8.18 (d, J = 8.0 Hz, 1H), 8.32 (dd, J = 7.6 Hz,
J = 0.8 Hz, 1H). 13C NMR (100 MHz, CDCl3): d ppm
55.52, 116.12, 118.47, 123.72, 125.88, 127.66, 127.76, 128.51,
128.66, 128.81, 133.04, 135.11, 137.74, 137.89, 142.27, 152.36,
161.66, 176.64. HRMS-EI m/z calcd for [M]+: 415.9944,
found: 415.9946.
2.3.34. 3-(2-Ethylbenzenethio)-4-chloro-9H-thioxanthen-9-one
10,10-dioxide (5o)
The pure compound was obtained as a pale-yellow powder
(yield 71%). Mp 215–216 C. 1H NMR (400 MHz, CDCl3):
d ppm 1.19 (t, J= 7.6 Hz, 3H), 2.75 (q, J= 7.5 Hz, 2H),
6.78 (d, J= 8.8 Hz, 1H), 7.34 (t, J= 7.2 Hz, 1H), 7.46–7.56
(m, 3H), 7.78 (t, J= 7.6 Hz, 1H), 7.91 (t, J= 7.6 Hz, 1H),
8.06 (d, J= 8.4 Hz, 1H), 8.19 (d, J= 7.6 Hz, 1H), 8.32 (d,
J= 8.0 Hz, 1H). 13C NMR (100 MHz, CDCl3): d ppm
15.36, 27.30, 123.73, 126.24, 126.92, 127.76, 127.79, 127.96,
128.52, 128.81, 130.23, 131.54, 133.06, 135.12, 137.50, 137.97,
142.24, 149.32, 151.28, 176.61. HRMS-EI m/z calcd for
[M]+: 414.0151, found: 414.0158.
2.3.35. 3-(3-Ethoxyphenylthio)-4-chloro-9H-thioxanthen-9-one
10,10-dioxide (5p)
The pure compound was obtained as a pale-yellow powder
(yield 81%). Mp 226–228 C. 1H NMR (400 MHz, CDCl3):
d ppm 1.43 (t, J= 7.0 Hz, 3H), 4.06 (q, J= 7.1 Hz, 2H),
7.01 (d, J= 8.8 Hz, 1H), 7.06–7.10 (m, 2H), 7.16 (d,
J= 7.6 Hz, 1H), 7.43 (t, J= 8.0 Hz, 1H), 7.78 (t,
J= 7.0 Hz, 1H), 7.91 (t, J= 7.4 Hz, 1H), 8.09 (d,
J= 8.8 Hz, 1H), 8.18 (d, J= 8.0 Hz, 1H), 8.33 (d,
J= 7.6 Hz, 1H). 13C NMR (100 MHz, CDCl3): d ppm
14.68, 63.85, 117.30, 121.13, 123.73, 126.20, 127.75, 127.79,
127.97, 128.53, 128.79, 129.14, 129.27, 131.30, 133.06, 135.15,
137.96, 142.25, 151.39, 160.27, 176.61. HRMS-EI m/z calcd
for [M]+: 430.0100, found: 430.0100.
2.3.36. 4-Chloro-3-(4-isopropylbenzenethio)9H-thioxanthen-9-
one 10,10-dioxide (5q)
The pure compound was obtained as a pale-yellow powder
(yield 66%). Mp 264–266 C. 1H NMR (400 MHz, CDCl3):
d ppm 1.32 (d, J= 6.8 Hz, 6H), 3.00 (sep, J= 7.0 Hz, 1H),
6.96 (d, J= 8.8 Hz, 1H), 7.39 (d, J= 8.0 Hz, 2H), 7.50 (d,
J= 8.4 Hz, 2H), 7.78 (td, J= 7.4 Hz, J= 1.2 Hz, 1H), 7.91
(td, J= 7.8 Hz, J= 1.1 Hz, 1H), 8.09 (d, J= 8.8 Hz, 1H),
8.18 (d, J= 7.6 Hz, 1H), 8.32 (dd, J= 8.0 Hz, J= 0.8 Hz,
1H). 13C NMR (100 MHz, CDCl3): d ppm 23.78, 34.05,
123.73, 125.00, 126.05, 127.70, 127.82, 128.51, 128.74, 128.81,
128.92, 133.04, 135.12, 136.03, 137.92, 142.28, 151.91, 152.01,
176.63. HRMS-EI m/z calcd for [M]+: 428.0308, found:
428.0314.
2.3.37. 4-Chloro-3-(2-isopropylphenylthio)-9H-thioxanthen-9-
one 10,10-dioxide (5r)
The pure compound was obtained as a pale-yellow powder
(yield 66%). Mp 226–228 C. 1H NMR (400 MHz, CDCl3):
d ppm 1.20 (d, J= 6.8 Hz, 6H), 3.39 (sep, J= 6.9 Hz, 1H),
6.78 (d, J= 8.4 Hz, 1H), 7.33 (td, J= 7.3 Hz, J= 1.6 Hz,
1H), 7.51–7.58 (m, 3H), 7.78 (td, J= 7.8 Hz, J= 1.2 Hz,Please cite this article in press as: Chen, C.-L. et al., Synthesis and evaluation of n
agents. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.20151H), 7.91 (td, J= 7.4 Hz, J= 1.1 Hz, 1H), 8.07 (d,
J= 8.8 Hz, 1H), 8.19 (dd J= 8.0 Hz, J= 0.8 Hz, 1H), 8.32
(dd, J= 8.0 Hz, J= 0.8 Hz, 1H). 13C NMR (100 MHz,
CDCl3): d ppm 23.86, 31.14, 123.73, 126.15, 126.37, 127.46,
127.70, 127.76, 127.80, 128.53, 128.57, 128.82, 131.74, 133.07,
135.13, 137.44, 137.96, 142.23, 151.62, 153.79, 176.61.
HRMS-EI m/z calcd for [M]+: 428.0308, found: 428.0306.
2.3.38. 3-(Benzylthio)-4-chloro-9H-thioxanthen-9-one 10,10-
dioxide (5s)
The pure compound was obtained as a pale-yellow powder
(yield 32%). Mp 214–215 C. 1H NMR (400 MHz, CDCl3):
d ppm 4.30 (s, 2H), 7.32–7.45 (m, 5H), 7.52 (d, J= 8.4 Hz,
1H), 7.79 (td, J= 7.4 Hz, J= 1.2 Hz, 1H), 7.91 (td,
J= 7.7 Hz, J= 0.9 Hz, 1H), 8.17 (d, J= 8.0 Hz, 1H), 8.24
(d, J= 8.8 Hz, 1H), 8.34 (dd, J= 7.6 Hz, J= 0.8 Hz, 1H).
13C NMR (100 MHz, CDCl3): d ppm 36.69, 123.74, 127.31,
127.58, 127.90, 128.08, 128.13, 128.53, 128.74, 128.83, 129.02,
133.08, 133.99, 135.17, 137.94, 142.18, 149.51, 176.62.
HRMS-EI m/z calcd for [M]+: 399.9995, found: 399.9994.
2.4. Cell culture and MTT assay
The human breast carcinoma cell lines, MCF-7 and MDA-
MB-468 (both obtained from the American Type Culture Col-
lection, USA) as well as the rat cardiac myoblast cell line H9C2
(obtained from the Food Industry Research and Development
Institute, Taiwan) were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) (Gibco BRL, USA) supplemented
with 10% heat-inactivated fetal bovine serum (FBS) in a
humidified, 5% (v/v) CO2 atmosphere at 37 C.
A 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbro-
mide (MTT) (Sigma, USA) assay was performed to determine
the cell viability and IC50 values (the concentration of drug
required to inhibit cell growth by 50% of the mean) of our syn-
thetic compounds against the MCF-7, MDA-MB-468, and
H9C2 cell lines (Mosmann, 1983; Denizot and Lang, 1986).
MCF-7 (3000 cells/well), MDA-MB-468 (5000 cells/well), and
H9C2 (104 cells/well) cells were seeded in 96-well microplates
with DMEM supplemented with 10% FBS and treated with
various concentrations of compounds for 72 h. After treat-
ment, plates were washed with phosphate-buffered saline
(PBS) three times, 100 lL of the MTT solution (0.5 mg/mL
final concentration in the medium) was added to each well,
and cells were incubated at 37 C for 1 h. MTT is converted
to blue formazan crystals by mitochondrial succinate dehydro-
genase. The plates were then washed with PBS and solubilized
in 100 lL of dimethyl sulfoxide (DMSO) per well. The absor-
bances at 540 nm were determined using an enzyme-linked
immunosorbent assay (ELISA) microplate reader. Effects of
our synthetic compounds on cell viability were demonstrated
as the relative activity (relative to the DMSO control group).
2.5. NCI in vitro 60-cell drug screening experiments
Eight of our synthesized compounds were selected by the NCI,
and their anticancer activities at a dose of 10 lM were
determined by a sulforhodamine B (SRB) colorimetric
assay according to previous protocols (Kandeel et al.,
2015; Sikic, 1991; Monks et al., 1997; Chen et al.). Cellsew 3-substituted-4-chloro-thioxanthone derivatives as potent anti-breast cancer
.10.010
Table 1 Inhibition activities of our synthetic compounds on the cell viability of MCF-7 and MDA-MB-468 cell lines.
.
Compd. No. Cell type/MCF-7 Cell type/MDA-MB-468
R Cell viability %± SD (at 12.5 lM)a IC50 (lM)
b Cell viability %± SD (at 12.5 lM) IC50 (lM)
4a 91.2 ± 5.0 >25 50.2 ± 8.2 15.2
5a 101.9 ± 6.6 >25 71.6 ± 1.6 >25
4b 88.3 ± 11.3 >25 74.4 ± 9.7 >25
5b 91.8 ± 6.4 >25 68.6 ± 0.9 >25
4c 84.5 ± 3.5 –c 69.4 ± 7.9 –
5c 95.6 ± 12.7 – 104.0 ± 9.4 –
4d 78.1 ± 8.0 – 90.9 ± 9.8 –
5d 81.5 ± 5.2 – 70.4 ± 5.0 –
4e 89.8 ± 8.0 >25 84.1 ± 3.3 >25
5e 81.9 ± 4.6 >25 47.9 ± 4.9 12.1
4f 41.8 ± 6.2 7.9 23.9 ± 1.7 3.9
5f 76.2 ± 5.8 >25 54.7 ± 2.7 18.6
4g 88.8 ± 2.3 – 68.8 ± 5.9 –
5g 87.0 ± 4.9 – 57.4 ± 5.8 –
4h 51.6 ± 4.4 10.7 21.4 ± 7.3 7.9
5h 74.8 ± 1.4 >25 42.7 ± 2.2 4.0
4i 72.1 ± 8.7 >25 72.3 ± 5.4 >25
5i 86.5 ± 6.8 >25 42.0 ± 1.3 7.8
4j 80.1 ± 9.2 – 66.4 ± 1.4 –
5j 97.8 ± 5.5 – 86.7 ± 7.3 –
4k 91.1 ± 7.0 – 93.8 ± 5.5 –
5k 96.0 ± 8.0 – 93.2 ± 8.6 –
4l 65.6 ± 10.2 – 69.7 ± 9.4 –
5l 88.1 ± 7.1 – 75.2 ± 5.3 –
4m 99.5 ± 7.5 – 91.1 ± 8.4 –
5m 77.6 ± 9.0 – 72.9 ± 3.0 –
4n 64.0 ± 8.2 >25 73.4 ± 7.2 >25
5n 76.3 ± 3.1 >25 48.5 ± 3.6 11.8
(continued on next page)
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Table 1 (continued)
Compd. No. Cell type/MCF-7 Cell type/MDA-MB-468
R Cell viability %± SD (at 12.5 lM)a IC50 (lM)
b Cell viability %± SD (at 12.5 lM) IC50 (lM)
4o 78.1 ± 3.3 – 70.2 ± 6.0
5o 75.1 ± 10.3 – 51.4 ± 3.8 –
4p 92.2 ± 8.1 – 78.5 ± 6.2 –
5p 88.4 ± 8.1 – 86.6 ± 6.7 –
4q 90.3 ± 4.2 >25 95.6 ± 5.7 >25
5q 82.5 ± 8.0 >25 50.0 ± 5.7 12.5
4r 93.3 ± 2.3 – 69.0 ± 5.1 –
5r 76.3 ± 5.0 – 46.4 ± 1.0 –
4s 63.5 ± 8.9 >25 36.6 ± 11.3 7.2
5s 109.7 ± 5.2 >25 66.6 ± 1.3 >25
Doxorubicind 9.0 ± 0.8 0.13 4.01 ± 0.1 0.04
a SD: standard derivation, and all experiments were independently performed at least three times.
b IC50 is the concentration of drug (lM) required to inhibit cell growth by 50% of the mean (N= 3).
c –: not determined.
d Doxorubicin as a reference drug.
Table 2 Cytotoxic effects of our synthetic compounds toward
the cardiac myoblast cell line H9C2.
Cell type/H9C2
Compd. No. IC50
a Compd. No. IC50
4a >25 5h >25
5a >25 4i >25
4f >25 5i >25
5f >25 4s 7.5
4h >25 5s >25
Doxorubicinb 0.16
a IC50 is the concentration of drug (lM) required to inhibit cell
growth by 50% of the mean (N= 5).
b Doxorubicin as a reference drug.
10 C.-L. Chen et al.(5000–10,000 cell/100 lL/well) were seeded into 96-well micro-
titer plates for 24 h at 37 C, with 5% CO2, 95% air, and 100%
relative humidity. Two plates of each cell line were fixed with
trichloroacetic acid (TCA) as a control of the cell population
for each cell line at the time of drug exposure (T0). After
additional incubation with the vehicle (DMSO) or the test
compounds for 48 h, cells were fixed with cold 50% (w/v)
TCA (final concentration, 10% TCA) and then incubated for
60 min at 4 C. Plates were then washed with tap water, and
cells were treated with 100 lL of the SRB solution at 0.4%
(w/v) in 1% acetic for 10 min at room temperature.
After staining, the plates were washed with 1% acetic acid
to remove any unbound dye, and SRB-bound cells werePlease cite this article in press as: Chen, C.-L. et al., Synthesis and evaluation of n
agents. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015solubilized with 0.01 M Trizma base. The absorbance was
measured using a spectrophotometer at a wavelength of
515 nm. Using the absorbance measurements, including time
zero (T0), control growth (C), and test growth in the presence
of a drug (TX), the percentage growth was calculated for each
compound as 100 – [(TX – T0)/(C – T0)]  100 for concentra-
tions for which TXP T0.
3. Results and discussion
The synthetic methods of 3-substituted-4-chloro-thioxan
thones are depicted in Scheme 1. The intermediate 2-((2,3-dic
hlorophenyl)thio)benzoic acid (3) was obtained from the reac-
tion of 2,3-dichlorobenzenethiol (1) with 2-iodobenzoic acid
(2) via the Ullmann condensation reaction (Jı´lek et al., 1981).
It is a common reaction to provide phenylthiobenzoic acid
products through copper-catalysis in basic conditions
(Brindle and Doyle, 1983; Paiva et al., 2013). The formation
of the thioxanthone ring was established by Friedel–Crafts
intramolecular ring closure of phenylthiobenzoic acid in con-
centrated acid conditions (Lory et al., 2006). Herein, it was
carried out in a miniclave and produced 3,4-dichloro-9H-
thioxanthen-9-one (4a) from 2-((2,3-dichlorophenyl)thio)ben
zoic acid (3) in sulfuric acid. Subsequently, oxidation of com-
pound 4a with excess 30% hydrogen peroxide in acetic acid
provided the desired S,S-dioxidethioxanthone derivative, 5a.
This oxidative protocol was previously reported for similar
thioxanthone derivatives (Harfenist et al., 1997). In addition,
the chloro group was shown to be the reactive halide underew 3-substituted-4-chloro-thioxanthone derivatives as potent anti-breast cancer
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Table 3 In-vitro anticancer activities of selected compounds against the NCI’s 60 human cancer cell lines at a dose of 10 lM.
Compd. No. 4b 5b 4f 5f 4j 5j 4s 5s
Leukemia
CCRF-CEM 96.58a 102.82 68.42 99.24 88.07 87.93 59.07 106.21
HL-60(TB) 103.53 82.90 105.61 94.23 109.07 87.56 115.59 93.37
K-562 101.65 82.93 96.64 90.81 97.86 82.58 86.95 91.94
MOLT-4 99.77 87.52 94.77 93.35 104.33 82.83 98.34 91.78
RPMI-8226 102.11 101.12 88.56 101.79 101.60 98.55 89.98 105.73
SR 91.41 85.05 51.19 82.91 95.93 94.42 36.57 75.48
Non-Small Cell Lung Cancer
A549/ATCC N.Tb 99.02 N.T. 99.70 N.T. 95.68 N.T. 89.11
EKVX 94.90 102.97 73.14 N.T. 103.89 107.10 93.46 91.59
HOP-62 N.T. 103.53 N.T. 103.42 N.T. 105.94 94.64 96.14
HOP-92 76.04 N.T. 49.52 N.T. 88.79 N.T. 74.60 N.T.
NCI-H226 85.36 93.29 81.05 94.97 109.77 94.92 90.97 97.05
NCI-H23 84.67 98.36 83.03 97.89 93.96 98.33 97.59 95.49
NCI-H322M 96.11 98.13 56.53 95.78 113.78 113.47 70.18 82.25
NCI-H460 108.87 93.95 40.25 106.17 110.85 106.80 29.14 91.01
NCI-H522 84.11 83.21 80.48 78.75 100.28 77.04 95.48 71.46
Colon Cancer
COLO 205 103.82 108.11 87.02 104.36 110.46 105.93 63.36 102.21
HCC-2998 106.34 91.97 98.92 107.20 103.54 107.26 101.78 112.10
HCT-116 98.18 109.18 54.33 111.75 105.21 109.55 41.74 103.56
HCT-15 92.60 99.39 85.15 93.70 99.05 95.76 82.20 99.25
HT29 102.56 100.42 86.36 95.26 103.86 100.49 60.70 84.13
KM12 99.82 104.68 73.79 105.30 113.08 106.11 104.90 94.44
SW-620 96.96 108.52 75.00 107.86 105.40 111.40 69.53 107.82
CNS Cancer
SF-268 93.39 102.54 81.14 109.30 98.33 111.63 100.29 100.86
SF-295 100.33 90.22 57.86 N.T. 98.15 110.51 63.22 92.38
SF-539 104.85 99.54 86.15 102.71 106.48 103.32 102.89 101.87
SNB-19 98.01 101.18 74.97 109.81 N.T. 108.78 83.57 102.12
SNB-75 82.75 90.38 76.16 69.89 90.00 91.69 75.12 93.26
U251 94.85 98.85 47.77 95.36 95.70 93.30 38.89 96.08
Melanoma
LOX IMVI 96.25 90.45 63.24 96.98 105.37 96.12 62.94 99.88
MALME-3M 92.44 92.54 76.90 93.20 100.81 100.01 93.38 88.53
M14 104.30 114.69 89.62 121.73 105.63 120.38 102.67 112.72
MDA-MB-435 103.22 104.68 85.11 N.T. 107.09 111.18 91.01 113.12
SK-MEL-2 104.71 91.45 105.36 106.10 108.94 101.47 116.81 97.20
SK-MEL-28 113.07 103.82 114.93 105.05 110.00 110.53 119.10 96.40
SK-MEL-5 95.50 86.36 88.35 95.87 104.77 95.48 99.73 89.67
UACC-257 102.79 110.31 99.23 92.72 92.09 101.98 109.84 125.12
UACC-62 79.70 102.84 82.23 109.94 N.T. 110.25 90.92 107.30
Ovarian Cancer
IGROV1 91.62 97.32 53.39 98.53 98.49 90.85 56.63 92.40
OVCAR-3 108.01 115.25 90.37 114.82 113.05 109.68 76.97 105.54
OVCAR-4 99.56 104.89 31.58 106.65 107.51 99.38 15.10 67.71
OVCAR-5 104.51 117.99 107.36 113.92 96.86 98.32 94.34 114.57
OVCAR-8 94.68 108.40 64.49 105.95 96.86 99.92 82.11 108.67
NCI/ADR-RES 96.88 98.90 81.27 104.52 105.14 103.89 90.62 101.50
SK-OV-3 96.13 N.T. 73.85 N.T. 111.32 N.T. 94.39 N.T.
Renal Cancer
786-0 111.45 112.17 84.66 109.42 108.98 108.37 78.53 104.97
ACHN 94.03 105.62 39.55 102.25 103.68 102.06 26.15 101.35
CAKI-1 84.00 90.76 48.21 N.T. 89.35 90.92 54.75 84.92
RXF 393 110.95 91.68 97.81 100.63 N.T. 97.45 106.84 90.20
SN12C 87.55 108.02 70.19 105.54 N.T. 106.63 79.25 104.91
TK-10 97.85 106.38 88.86 94.36 99.22 125.54 95.49 112.29
UO-31 73.68 86.73 69.61 89.01 87.03 81.81 66.76 84.49
(continued on next page)
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Table 3 (continued)
Compd. No. 4b 5b 4f 5f 4j 5j 4s 5s
Prostate Cancer
PC-3 90.81 97.31 77.10 100.05 98.56 103.79 83.92 92.23
DU-145 108.05 102.97 108.68 106.84 109.56 113.24 107.70 98.04
Breast Cancer
MCF7 82.14 79.36 83.90 63.74 94.01 90.83 89.62 80.93
MDA-MB-231/ATCC 93.94 119.41 77.55 118.77 108.12 114.68 71.98 109.91
HS 578T 119.59 129.54 102.79 108.91 107.64 106.46 91.28 93.13
BT-549 107.30 113.52 87.92 115.29 105.28 127.71 84.98 101.74
T-47D 87.90 89.24 85.63 93.01 97.56 93.42 82.55 88.91
MDA-MB-468 82.54 86.23 87.73 80.41 113.20 90.91 73.81 82.09
Mean 96.75 99.62 78.44 100.11 102.52 101.62 81.22 96.83
Delta 23.07 20.26 46.86 36.37 15.49 24.58 66.12 29.12
Range 45.91 50.18 83.35 57.99 26.75 50.67 104.00 57.41
a Data obtained from NCI in vitro 60-cell drug screen program at 10 lM concentration. The values reported are the growth percentages
determined relative to the no-drug control at time zero. The values of growth percentages are between 0 and 100. A value of 0 represents no net
growth over the course of the experiment and a value of 100 represents no growth inhibition.
b N.T.: Not tested.
12 C.-L. Chen et al.vigorous conditions in direct nucleophilic aromatic substitu-
tion reactions (Sharghi and Tamaddon, 2001). Hence, the syn-
thetic strategy of compounds 4b–4s, and 5b–5s was
accomplished via the reaction of an appropriate benzenethiol
with compound 4a or 5a in methanol/tetrahydrofuran then
treatment with sodium methoxide to obtain the desired com-
pounds, which were purified by recrystallization. Herein, the
position of the nucleophilic substituent on thioxanthone and
the structure of compound 4c were confirmed by X-ray
(Fig. S1). All synthetic methods are summarized in the general
procedure section (i–v).
The effects of the synthesized thioxanthone derivatives 4a–
5s on cell viability of the MCF-7 and MDA-MB-468 breast
cancer cell lines were experimentally assessed by performing
a MTT assay. Results are illustrated in Table 1 and are
expressed as percentages of cell viability. From the obtained
results, we observed that some thioxanthone derivatives exhib-
ited interesting anticancer activities on the tested cell lines. We
found that the most potent compounds against MCF-7 cells
were 4f and 4h with respective cell viability values of 41.8
± 6.2% and 51.6 ± 4.4%, respectively at the concentration
of 12.5 lM. In addition, the most potent compounds against
MDA-MB-468 cells were 4a (50.2 ± 8.2%), 4f (23.9
± 1.7%), 4h (21.4 ± 7.3%), 4s (36.6 ± 11.3%), 5e (47.9
± 4.9%), 5h (42.7 ± 2.2%), 5i (42.0 ± 1.3%), 5n (48.5
± 3.6%), 5q (50.0 ± 5.7%), and 5r (46.4 ± 1.0%) which
showed low percentages of cell viability at a concentration of
12.5 lM. Of the compounds analyzed, we observed that intro-
duction of substituted phenylthio groups at the 3-position of
the thioxanthone scaffold could modulate the inhibition of cell
viability of MCF-7 and MDA-MB-468 compared to the thiox-
anthone derivatives 4a and 5a which possess two chloro
groups.
Further, the micromolar IC50 values of some potent com-
pounds are presented in Table 1. Some thioxanthone deriva-
tives showed IC50 values in the low micromolar range.
Among these, compounds 4f (IC50 = 7.9 lM) and 4h
(IC50 = 10.7 lM) showed potent inhibitory effects on cell
viability of MCF-7 cells. In addition, compounds 4fPlease cite this article in press as: Chen, C.-L. et al., Synthesis and evaluation of n
agents. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015(IC50 = 3.9 lM), 4h (IC50 = 7.9 lM), 4s (IC50 = 7.2 lM), 5e
(IC50 = 12.1 lM), 5h (IC50 = 4.0 lM), 5i (IC50 = 7.8 lM),
5n (IC50 = 11.8 lM), and 5q (IC50 = 12.5 lM) showed potent
inhibitory effects on cell viability of MDA-MB-468 cells. We
found that the thioxanthone derivatives 4f, 4h, and 5h possess-
ing para-substituted phenylthio groups were more potent in
inhibiting the cell viability of the tested cell lines compared
to 4b and 5b. Based on these results, we concluded that the
para-substituted phenylthio groups might be important for
the inhibition activities of this class of compounds on the cell
viability. Moreover, the cytotoxic effects of our compounds
toward the normal cardiac myoblast H9C2 cells were also
determined (Table 2). Interestingly, the tested compounds
showed IC50 values of >25 lM toward H9C2 cells except
for compound 4s (IC50 = 7.5), suggesting that they had slight
or no cytotoxicity toward normal cell H9C2 cells at concentra-
tions higher than that needed to inhibit breast cancer. We
found that the most-active compound was 4f which was
active against MCF-7 and MDA-MB-468 cells with IC50
values of 7.9 and 3.9 lM, respectively. Furthermore, it did
not impair cell viability of the cardiac myoblast H9C2 cells
(IC50 > 25 lM).
In addition, the effects of compounds 4b, 5b, 4f, 5f, 4j, 5j,
4s, and 5s on cell viability were evaluated against the NCI’60
human cancer cell lines at a single dose (10 lM) in vitro using
the SRB protein-binding dye (Kandeel et al., 2015; Sikic, 1991;
Monks et al., 1997; Chen et al.). Results, expressed as a growth
percentage, mean growth, range of growth, and growth rela-
tive to the most-sensitive cell lines are summarized in Table 3
and Figs. S2–S9. Results showed that compound 4f was still
the most active among the tested compounds with a minimum
mean growth percentage of 78.44. Maximum inhibition was
observed for non-small cell lung cancer (HOP-92 and NCI-
H460), CNS cancer (U251), ovarian cancer (OVCAR-4), and
renal cancer (ACHN and CAKI-1) with growth percentages
less than 50% as shown in Table 3. The next potent compound
was 4s which showed a mean growth percentage of 81.22, and
it could impair the proliferation of cardiac myoblast H9C2
cells (IC50 = 7.5 lM) in our test.ew 3-substituted-4-chloro-thioxanthone derivatives as potent anti-breast cancer
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Because of the anticancer potential demonstrated by the
thioxanthone scaffold, an approach for synthesizing
3-substituted-4-chloro-thioxanthones and their corresponding
S,S-dioxidethioxanthone derivatives was developed, and the
inhibition activities of the synthesized compounds on cell
viability were evaluated. Based on our biological data, it was
envisioned that introducing different phenylthio groups at
the 3-position of the thioxanthone scaffold caused loss of cell
viability of the breast cancer cell lines MCF-7 and MDA-
MB-468 cells. Among the synthesized compounds, 4f (with a
4-chlorophenylthio group) was the most-active compound
exhibiting potent inhibitory activity on the cell viability of
MCF-7 and MDA-MB-468 cells. Interestingly, compound 4f
did not impair the cell viability of cardiac myoblast H9C2 cells
at concentrations higher than that needed to inhibit breast
cancer. Moreover, compound 4f also appeared to be the best
anticancer member of our compounds with the minimum
mean growth percentage for the NCI drug screening program
experiments. Through a series of promising in vitro experi-
ments, we found that 3-substituted-4-chloro-thioxanthone
derivatives, especially compound 4f, exhibited preferential
growth inhibition effects toward several cancer cell lines. Based
on our results and structure–activity relationship studies,
compound 4f could be a potent anti-breast cancer candidate
and promising lead compound that warrants further structure
optimization.
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